Rein Therapeutics Inc. (RNTX)
$0.75-3.85%Close
BUYCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $21M
- Beta
- 1.35
- P/E (TTM)
- -0.41
- Short % float
- 3.05%
- Days to cover
- 2.4
- SI change
- -2.9%
- 1W
- -8.54%
- 1M
- -5.06%
- vs SPY 1W
- -8.40%
- vs SPY 1M
- -7.57%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 5
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-140.7%
REV YoY-
ROE-234.5%
EPS YoY-
ROA-75.4%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.41
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.25
P/FCF-
EV/EBITDA-0.60
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO4.27
ND/EBITDA-
BETA1.35
Company news
FAQ
- What is LOPJLB’s current signal on RNTX?
- LOPJLB’s latest quantitative signal on Rein Therapeutics Inc. (RNTX) is BUY in a CRISIS regime. Signals are updated daily.
- What market regime is RNTX in?
- Rein Therapeutics Inc. (RNTX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Rein Therapeutics Inc. (RNTX) do?
- Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, …